Donald R. Dengel, PhD, professor in the School of Kinesiology and director of the Laboratory of Integrative Human Physiology, is a co-author of an article recently published in the journal, Obesity, entitled “Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.” The article evaluates the effect of 52 weeks of exenatide extended release (XR) on the maintenance of meal replacement therapy (MRT)-induced body mass index reduction in adolescents with severe obesity. The authors concluded that exenatide XR, when compared with a placebo, may partly mitigate the propensity toward BMI rebound in adolescents who achieved initial weight loss with dietary intervention.